S&P 500   3,635.41 (+1.62%)
DOW   30,046.24 (+1.54%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
S&P 500   3,635.41 (+1.62%)
DOW   30,046.24 (+1.54%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
S&P 500   3,635.41 (+1.62%)
DOW   30,046.24 (+1.54%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
S&P 500   3,635.41 (+1.62%)
DOW   30,046.24 (+1.54%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
Log in
NASDAQ:NVET

Nexvet Biopharma plc - Ordinary Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$6.72
0.00 (0.00 %)
(As of 08/10/2017)
Add
Today's Range
$6.72
Now: $6.72
$6.72
50-Day Range N/A
52-Week Range
$2.75
Now: $6.72
$6.76
VolumeN/A
Average Volume38,104 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company's platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal's immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company's advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).
Read More
Nexvet Biopharma plc - Ordinary logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.83 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:NVET
CUSIPN/A
Phone+353-1-2158100
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive NVET News and Ratings via Email

Sign-up to receive the latest news and ratings for NVET and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Nexvet Biopharma plc - Ordinary (NASDAQ:NVET) Frequently Asked Questions

What stocks does MarketBeat like better than Nexvet Biopharma plc - Ordinary?

Wall Street analysts have given Nexvet Biopharma plc - Ordinary a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nexvet Biopharma plc - Ordinary wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Nexvet Biopharma plc - Ordinary's earnings last quarter?

Nexvet Biopharma plc - Ordinary (NASDAQ:NVET) announced its earnings results on Thursday, May, 11th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02.
View Nexvet Biopharma plc - Ordinary's earnings history
.

What other stocks do shareholders of Nexvet Biopharma plc - Ordinary own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nexvet Biopharma plc - Ordinary investors own include Frontline (FRO), Achillion Pharmaceuticals (ACHN), Anthera Pharmaceuticals (ANTH), Sphere 3D (ANY), Arena Pharmaceuticals (ARNA), Yamana Gold (AUY), BioLineRx (BLRX), Caladrius Biosciences (CLBS), Genetic Technologies (GENE) and Keryx Biopharmaceuticals (KERX).

When did Nexvet Biopharma plc - Ordinary IPO?

(NVET) raised $58 million in an IPO on Thursday, February 5th 2015. The company issued 4,000,000 shares at $13.00-$16.00 per share. BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Piper Jaffray and JMP Securities were co-managers.

What is Nexvet Biopharma plc - Ordinary's stock symbol?

Nexvet Biopharma plc - Ordinary trades on the NASDAQ under the ticker symbol "NVET."

What is Nexvet Biopharma plc - Ordinary's stock price today?

One share of NVET stock can currently be purchased for approximately $6.72.

What is Nexvet Biopharma plc - Ordinary's official website?

The official website for Nexvet Biopharma plc - Ordinary is www.nexvet.com.

How can I contact Nexvet Biopharma plc - Ordinary?

Nexvet Biopharma plc - Ordinary's mailing address is Unit 5 Sragh Technology Park, Rahan Road, TULLAMORE, R35 FR98, Ireland. The biopharmaceutical company can be reached via phone at +353-1-2158100.

This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.